1.Occult Hepatitis B Virus Infection in Chronic Hepatitis C.
The Korean Journal of Gastroenterology 2013;62(3):154-159
Occult HBV infection is defined as the presence of HBV DNA in the liver (with or without detectable or undetectable HBV DNA in the serum) of individuals testing negative for HBsAg. Studies on occult HBV infection in hepatitis C patients have reported highly variable prevalence, because the prevalence of occult HBV infection varies depending on the hepatitis B risk factors and methodological approaches. The most reliable diagnostic approach for detecting occult HBV detection is through examination of liver DNA extracts. HCV has been suspected to strongly suppress HBV replication up to the point where it may be directly responsible for occult HBV infection development. However, more data are needed to arrive at a definitive conclusion regarding the role of HCV in inducing occult HBV infection. Occult HBV infection in chronic hepatitis C patients is a complex biological entity with possible relevant clinical implications. Influence of occult HBV infection on the clinical outcomes of chronic hepatitis C may be considered negative. However, recent studies have shown that occult HBV infection could be associated with the development of hepatocellular carcinoma and contribute to the worsening of the course of chronic liver disease over time in chronic hepatitis C patients. Nevertheless, the possible role of occult HBV infection in chronic hepatitis C is still unresolved and no firm conclusion has been made up until now. It still remains unclear how occult HBV infection affects the treatment of chronic hepatitis C. Therefore, in order to resolve current controversies and understand the pathogenic role and clinical impacts of occult HBV infection in chronic hepatitis C patients, well-designed clinical studies are needed.
Carcinoma, Hepatocellular/complications
;
DNA, Viral/analysis
;
Hepacivirus/genetics
;
Hepatitis B/*complications/*diagnosis/drug therapy
;
Hepatitis B virus/genetics
;
Hepatitis C, Chronic/*complications/*diagnosis/drug therapy
;
Humans
;
Interferon-alpha/therapeutic use
;
Liver/virology
;
Liver Neoplasms/complications
2.Life quality analysis of hepatitis C patients with liver cirrhosis undergoing antiviral therapy following splenectomy.
Guangxi JI ; Yonghong GUO ; Lin CHEN ; Ying ZHANG ; Yu HE ; Li MA ; Yu WANG ; Zhiyuan MA ; Cheng CHENG ; Zhansheng JIA
Chinese Journal of Hepatology 2014;22(3):195-199
OBJECTIVETo evaluate the effect of antiviral therapy on the quality of life (QOL) of patients with chronic hepatitis C (CHC) and cirrhosis during the 5-year period following splenectomy to treat hypersplenism.
METHODSData of patients with CHC and cirrhosis who had undergone treatment for hypersplenism were retrospectively selected from the hospital database of medical records. The patients were first grouped according to the hypersplenism treatment: splenectomy (group A, 28 cases) and conservative/non-operative (group B, 30 cases). Sub-grouping was carried out according to the CHC treatment: interferon-alpha-2a and ribavirin (15 cases in the A1 group, and 19 cases in the B1 group) and non-antiviral (13 cases in the A2 group, and 11 cases in the B2 group). To determine the intergroup differences in QOL during the 5-year period following the hypersplenism treatment, the QOL was assessed by chronic liver disease questionnaire (CLDQ), listing of specific symptoms (SS), and the World Health Organization QOL scale (WHOQOL-BREF).
RESULTSBetween-group statistical comparison of the subjective feeling, physiological status, mental state, and social life relationship of the patients showed no significant differences among the patients who received splenectomy compared to those who received the conservative treatment. However, the QOL of splenectomy-treated patients who received non-antiviral CHC treatment was worse than that of the patients who were given conservative treatment for the hypersplenism and antiviral therapy for the CHC. The patients who received splenectomy and antiviral therapy had better QOL than the other patient group(3.69 +/- 0.75 vs 2.15 +/- 0.98, P = 0.0003).
CONCLUSIONSplenectomy followed by antiviral therapy may improve the QOL of patients with CHC-related cirrhosis and hypersplenism.
Adult ; Antiviral Agents ; therapeutic use ; Female ; Hepatitis C, Chronic ; complications ; drug therapy ; Humans ; Liver Cirrhosis ; drug therapy ; virology ; Male ; Middle Aged ; Quality of Life ; Retrospective Studies ; Splenectomy ; Treatment Outcome
3.Acute Exacerbation of Hepatitis in Liver Cirrhosis with Very High Levels of alpha-Fetoprotein But No Occurrence of Hepatocellular Carcinoma.
Jin Soo BAE ; Sang Jong PARK ; Kwang Bo PARK ; So Ya PAIK ; Jin Kyung RYU ; Chang Kyu CHOI ; Tae Joon HWANG
The Korean Journal of Internal Medicine 2005;20(1):80-85
Aminotransferase levels do not always increase during acute hepatitis or during an acute flare-up of chronic hepatitis. Persistently increased levels of serum alpha-Fetoprotein in an adult with liver disease suggest not only the presence or progression of hepatocellular carcinoma or its recurrence after hepatic resection or after other therapeutic approaches such as chemotherapy or chemoembolization, but also it suggests that there is an acute exacerbation of hepatitis or liver cirrhosis. We report here on two unusual cases of HBV- and HCV-related liver cirrhosis with acute exacerbation of hepatitis in which there was an insignificant elevation of the aminotransferase levels, but there were markedly increased alpha-Fetoprotein levels observed. The levels of alpha-Fetoprotein decreased gradually in both cases since the beginning of antiviral therapy, which implies that the increased levels were due to aggravation of the accompanying hepatitis. These cases also emphasize that using only the measurement of alpha-Fetoprotein is not sufficient for the diagnosis of hepatocellular carcinoma, and that this diagnosis also requires a more specific measurement such as AFP L3 along with the standard imaging studies.
Antiviral Agents/therapeutic use
;
Female
;
Hepatitis B, Chronic/*complications/drug therapy
;
Hepatitis C, Chronic/*complications/drug therapy
;
Humans
;
Liver Cirrhosis/virology
;
Male
;
Middle Aged
;
Transaminases/blood
;
alpha-Fetoproteins/*analysis
4.Antiviral treatment for cirrhosis due to hepatitis C: a review.
Aravindh SOMASUNDARAM ; Jayanthi VENKATARAMAN
Singapore medical journal 2012;53(4):231-235
Chronic hepatitis C infection is an important cause of cirrhosis and hepatocellular carcinoma (HCC). Antiviral therapy (AVT) for patients with cirrhosis due to hepatitis C may retard the progression of cirrhosis and prevent both the development of HCC as well as the recurrence of hepatitis C following liver transplantation. This review highlights the issues associated with AVT for patients with compensated and decompensated cirrhosis due to hepatitis C virus.
Antiviral Agents
;
therapeutic use
;
Carcinoma, Hepatocellular
;
prevention & control
;
virology
;
Disease Progression
;
Hepacivirus
;
Hepatitis C, Chronic
;
complications
;
drug therapy
;
Humans
;
Liver Cirrhosis
;
drug therapy
;
virology
;
Liver Neoplasms
;
prevention & control
;
virology
;
Liver Transplantation
;
Secondary Prevention
5.A case report of sustained virological response with PEG-interferon-α-2b in a patient with CML and hepatitis C prior fail in ten-year treatment of conventional interferon.
Chinese Journal of Hepatology 2013;21(10):783-784
Female
;
Hepatitis C
;
complications
;
drug therapy
;
Humans
;
Interferon-alpha
;
therapeutic use
;
Interferons
;
therapeutic use
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
complications
;
drug therapy
;
virology
;
Middle Aged
;
Polyethylene Glycols
;
therapeutic use
;
Recombinant Proteins
;
therapeutic use
;
Treatment Outcome
6.Review: Clinical Outcome after Living Donor Liver Transplantation in Patients with Hepatitis C Virus-associated Cirrhosis.
The Korean Journal of Hepatology 2007;13(4):489-494
No abstract available.
Drug Therapy, Combination
;
Hepacivirus
;
Hepatitis C, Chronic/complications/*diagnosis/therapy
;
Humans
;
Interferon Alfa-2a/therapeutic use
;
Liver Cirrhosis/*diagnosis/mortality/virology
;
*Liver Transplantation
;
Living Donors
;
Polyethylene Glycols/therapeutic use
;
Ribavirin/therapeutic use
;
Severity of Illness Index
;
Treatment Outcome
7.Synchronous Hepatocellular Carcinoma and B-Cell Non-Hodgkin's Lymphoma in Chronic Hepatitis C Patient.
Soon Il LEE ; Nae Yun HEO ; Seung Ha PARK ; Young Don JOO ; Il Hwan KIM ; Jeong Ik PARK ; Ji Yeon KIM ; Seung Ho KIM ; Hye Kyung SHIM
The Korean Journal of Gastroenterology 2014;64(3):168-172
Hepatitis C virus (HCV) is one of the main viral causes of hepatocellular carcinoma (HCC) and is associated with lymphoproliferative disorder such as non-Hodgkin's lymphoma (NHL). However, there are only few case reports on concomitantly induced NHL and HCC by HCV. Herein, we report a case of synchronous NHL and HCC in a patient with chronic hepatitis C which was unexpectedly diagnosed during liver transplantation surgery. This case suggests that although intrahepatic lymph node enlargements are often considered as reactive or metastatic lymphadenopathy in chronic hepatitis C patients with HCC, NHL should also be considered as a differential diagnosis.
Antineoplastic Agents/therapeutic use
;
Carcinoma, Hepatocellular/complications/*diagnosis/radiotherapy
;
Drug Therapy, Combination
;
Embolization, Therapeutic
;
Fluorodeoxyglucose F18
;
Gadolinium DTPA
;
Genotype
;
Hepatitis B virus/genetics
;
Hepatitis C, Chronic/complications/*diagnosis/*virology
;
Humans
;
Liver Neoplasms/complications/*diagnosis/radiotherapy
;
Lymph Nodes/pathology
;
Lymphoma, Non-Hodgkin/complications/*diagnosis/drug therapy
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Positron-Emission Tomography
;
Tomography, X-Ray Computed
8.Meta-analysis on peginterferon plus ribavirin in treatment of hepatitis C virus genotype 1 or 4 infection in HIV patients.
Si-Hai ZHAO ; En-Qi LIU ; Da-Xin CHENG ; Xin XUE ; Yong-Lie CHU
Journal of Zhejiang University. Medical sciences 2009;38(3):315-319
OBJECTIVETo perform a Meta-analysis on peginterferon with interferon in treatment of HIV patients coinfected with refractory genotype HCV.
METHODSA literature search of Medline was conducted to identify eligible randomized controlled trials. Meta analysis was conducted to evaluate peginterferon and interferon in treatment of coinfected HCV genotype 1 or 4 in HIV patients.
RESULTSix trials of 88 matched the selection criteria. Total 1,131 patients with coinfection of HCV genotype 1 or 4 and HIV were included. Sustain viral response was higher in patients treated with peginterferon plus ribavirin compared with that of interferon plus ribavirin (26 % compared with 8 %) or peginterferon alone (26 % compared with 13 %). Severe adverse effects and withdrawal rates were similar for patients treated with peginterferon and patients treated with interferon.
CONCLUSIONPeginterferon plus ribavirin in treatment of patients with coinfection of genotype 1 or 4 HCV and HIV can achieve higher sustain viral response and the likelihoods of serious adverse effects and withdrawal rates are similar to other therapies.
Adult ; Antiviral Agents ; administration & dosage ; Drug Therapy, Combination ; Female ; Genotype ; HIV Infections ; complications ; drug therapy ; immunology ; Hepacivirus ; classification ; genetics ; Hepatitis C, Chronic ; complications ; drug therapy ; virology ; Humans ; Interferon-alpha ; administration & dosage ; Male ; Polyethylene Glycols ; administration & dosage ; Randomized Controlled Trials as Topic ; Recombinant Proteins ; Ribavirin ; administration & dosage
9.Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
Hee Chul NAM ; Hae Lim LEE ; Hyun YANG ; Myeong Jun SONG
Clinical and Molecular Hepatology 2016;22(2):259-266
BACKGROUND/AIMS: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice. METHODS: Patients were treated with 60 mg of DCV once daily plus 200 mg of ASV twice daily for 24 weeks, and followed for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks after treatment (SVR12) and safety. RESULTS: This retrospective study included eight patients with chronic HCV genotype 1b infection. All of the enrolled patients were diagnosed with liver cirrhosis, and their mean age was 65.75 years. One patient was a nonresponder and two patients relapsed with previous pegylated interferon (PegIFN) and ribavirin (RBV) treatment. None of the patient showed NS5A mutation. An SVR12 was achieved in 88% of cases by the DCV and ASV combination therapy. The serum transaminase level and the aspartate-aminotransferase-to-platelet ratio were improved after the treatment. DCV and ASV were well tolerated in most of the patients, with treatment discontinuation due to adverse events (elevated liver enzyme and decompensation) occurring in two patients. CONCLUSIONS: In this study, combination of DCV and ASV treatment achieved a high sustained virological response with few adverse events even in those with cirrhosis, advanced age, and nonresponse/relapse to previous interferon-based therapy. Close monitoring of safety issues may be necessary when treating chronic HCV patients receiving DCV and ASV, especially in older patient and those with cirrhosis.
Aged
;
Alanine Transaminase/blood
;
Antiviral Agents/*therapeutic use
;
Aspartate Aminotransferases/blood
;
Drug Administration Schedule
;
Drug Resistance, Viral
;
Drug Therapy, Combination
;
Female
;
Genotype
;
Hepacivirus/*genetics/isolation & purification
;
Hepatitis C, Chronic/complications/*drug therapy/virology
;
Humans
;
Imidazoles/*therapeutic use
;
Isoquinolines/*therapeutic use
;
Liver/diagnostic imaging
;
Liver Cirrhosis/complications
;
Male
;
Middle Aged
;
RNA, Viral/blood
;
Retrospective Studies
;
Sulfonamides/*therapeutic use
;
Treatment Outcome
10.Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.
Kyung Hoon KIM ; Byoung Kuk JANG ; Woo Jin CHUNG ; Jae Seok HWANG ; Young Oh KWEON ; Won Young TAK ; Heon Ju LEE ; Chang Hyeong LEE ; Jeong Ill SUH
The Korean Journal of Hepatology 2011;17(3):220-225
BACKGROUND/AIMS: Pegylated interferon (peginterferon) and ribavirin combination therapy is less effective and associated with a higher frequency of serious complications in chronic hepatitis C patients with cirrhosis than in noncirrhotic patients. This study evaluated the efficacy and tolerability of peginterferon and ribavirin treatment in patients with hepatitis C virus (HCV)-related cirrhosis. METHODS: Eighty-six patients with clinically diagnosed liver cirrhosis were treated with either peginterferon alpha-2a (n=51) or peginterferon alpha-2b (n=35) plus ribavirin. The sustained virologic response (SVR) and adverse effects were analyzed retrospectively. RESULTS: Of the 86 patients (55 males), 48 patients (55.8%) had HCV genotype 1 infection and 38 (44.2%) had genotype non-1 infection. The overall SVR rate was 34.9% (30/86), and the rates of SVR in the genotype 1 and non-1 patients were 20.8% (10/48) and 52.6% (20/38), respectively. The multivariate analysis revealed that having HCV genotype 1 (P=0.003) and high baseline viral load (>8.0x10(5) IU/mL, P=0.012) were the independent predictive factors for SVR failure. In 20.9% (18/86) of the patients, treatment was not completed due to adverse events (27.8%), loss to follow-up (50.0%), and other reasons (22.2%). CONCLUSIONS: Peginterferon and ribavirin combination therapy was relatively effective and feasible for clinically diagnosed HCV patients, especially in those with genotype non-1 infection and low baseline viral load.
Adult
;
Aged
;
Antiviral Agents/*therapeutic use
;
Drug Therapy, Combination
;
Female
;
Genotype
;
Hepacivirus/*genetics
;
Hepatitis C, Chronic/complications/*drug therapy/virology
;
Humans
;
Interferon-alpha/*therapeutic use
;
Liver Cirrhosis/*diagnosis/etiology/virology
;
Male
;
Middle Aged
;
Polyethylene Glycols/*therapeutic use
;
RNA, Viral/blood
;
Recombinant Proteins/therapeutic use
;
Retrospective Studies
;
Ribavirin/*therapeutic use
;
Viral Load